Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stellar Biotechnologies has signed a marketing and sales agreement with SAFC, a provider of custom manufacturing and services.
Subscribe to our email newsletter
As per the agreement, Stellar will be responsible for producing KLH commercial intermediate and supplying all aquaculture-derived KLH intermediate required for production of SAFC cGMP KLH formulations.
However, SAFC will be responsible for selling, distributing and marketing cGMP-grade high molecular weight keyhole limpet hemocyanin (HMW KLH) that uses only Stellar aquaculture-derived KLH for applications in therapeutic vaccines.
Additionally, SAFC will manufacture HMW KLH under cGMP conditions and provide cGMP clinical and commercial manufacturing of bioconjugation services to support the development and manufacture of conjugate vaccines.
Stellar CEO Frank Oakes said they look forward to continuing growth in this relationship and will begin manufacture of SAFC’s initial order as soon as possible.